Albion Medical Holdings, Inc.

Albion Medical Holdings, Inc. specializes in developing allergy immunotherapy products and services, focusing on improving healthcare professionals' ability to diagnose and treat allergic conditions effectively. Albion Medical Holdings, Inc. is involved in the allergy immunotherapy sector, providing essential products and services to healthcare providers.

Founded in 1904 in Lenoir, US, the company has undergone strategic changes over the years. It was acquired by Ares Life Sciences in April 2013, with the terms of the investment undisclosed. Albion Medical Holdings, Inc. offers an array of allergy immunotherapy (AIT) products and services tailored for healthcare professionals.

Their core offerings include skin-testing extracts, various skin-testing devices, and extensive educational resources for medical staff. Additionally, they provide AIT formulation services via GREER® Pharmacy, supplying high-quality allergenic extracts for in-office mixing. The company's products aid healthcare providers in diagnosing and treating allergies, particularly focusing on allergens such as pollen, dust mites, and pet dander, serving a diverse clientele including allergists, clinics, and hospitals across the United States. Albion Medical Holdings, Inc.

generates revenue through direct sales of its allergy immunotherapy products and services to healthcare providers, primarily through business-to-business (B2B) interactions. Revenue is derived from customer orders, which may include bulk purchases of standardized allergenic extracts or subscription agreements for continuous supply. Their flagship products consist of standardized extracts for common allergens such as ragweed and cat hair, integral to therapeutic allergy management. Albion Medical Holdings, Inc.

plans to focus on developing new products to enhance their offerings in the allergy immunotherapy market. While specific upcoming product launches have not been detailed, the company aims to expand its reach into new geographic markets to meet growing demands for allergy management solutions. Recent funding from Ares Life Sciences, acquired in April 2013, is expected to support these strategic initiatives as they innovate and broaden their service capabilities.